System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Suayib Yalcin is an expert in Oncology at Hacettepe University (Turkey). As of October 2026, ScienceLeadR ranks Suayib Yalcin in the top 1% of experts worldwide for Gastrointestinal Neoplasms, Carcinoma and Intestinal Neoplasms. Suayib Yalcin has authored 517 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 3 of them ongoing. SLR score: 2,002 (community average: 125). How the SLR is computed.

LeadR Profile

Suayib Yalcin Hacettepe University Turkey
2 002 ScienceLeadR Reputation 2002

Unlock

Register Login
Network Map

Oncology

Subspecialties: Gastroenterology - Biochemistry - Hepatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1992 - 2026
Source: PubMed

Hacettepe University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 517

Citations

Citations: 18 748 1st author: 80 Last author: 148 Unique author: 16

Main journals

J Clin Oncol 30
Phys Rev Lett 28
Ann Oncol 25
J Clin Med 13
Springer eBooks 12

Best Journals

Ann Oncol 14
J Clin Oncol 7
Nature 4

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Radiological Response to Capecitabine and Temozolomide in an Elderly Patient with Metastatic Leiomyosarcoma: A Case Report.
PMID 42739672 — leiomyosarcoma, temozolomide, aged, therapeutics, capecitabine		J Clin Med20260
First-Line Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data from Turkey.
PMID 42590101 — carcinoma, hepatocellular, safety, immunotherapy, viruses, therapeutics, hepatitis		J Clin Med20260
Prognostic Value of the Vitamin B12/C-Reactive Protein Index in Resected Stage II-III Cutaneous Melanoma: Comparison with Its Individual Components.
PMID 42589863 — vitamins, melanoma, c-reactive protein, vitamin b 12		J Clin Med20260
Prognostic Significance and Primary-Metastatic Differences in VASH1 Expression, CD34-Defined Microvessel Density, and VEGF Expression in Colorectal Cancer.
PMID 42511662 — vascular endothelial growth factor a, neoplasms, colorectal neoplasms, microvessels, wounds and injuries, angiogenesis		Int J Mol Sci20260
Early Post-Treatment Eosinophil Elevation and Survival Outcomes in Metastatic Renal Cell Carcinoma Treated with First-Line VEGFR-TKI Monotherapy: A Turkish Multicenter Retrospective Cohort Study.
PMID 42512093 — cells, cohort studies, eosinophils, carcinoma, renal cell, therapeutics		Biomedicines20260

Clinical Studies 22

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 15
Phase 2 4
N/A 2
Phase 2/Phase 3 1

By status:

Completed 16
Active not recruiting 3
Approved for Marketing 1
No longer available 1
Recruiting 1

By type:

Interventional 20
Expanded Access 2

By Monocentric/Multicentric:

monocentric 4
multicentric2to4 0
multicentric5to9 2
multicentricup10 16

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Second Dose of Varicella Vaccine in Healthy Children
NCT07475000 — safety, vaccines, chickenpox, vaccination, aged, chickenpox vaccine, consent forms, child		Phase 3Recruiting2026
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2 positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147 — cells, lewy bodies, stomach, parkinson disease, esophagus, neoplasms, adenocarcinoma, drug therapy, oxaliplatin, fluorouracil, immunotherapy, receptors, death domain, esophageal neoplasms, capecitabine, cell death, stomach neoplasms, trastuzumab, chemotherapy		Phase 3Active not recruiting2021
Evaluation of Co formulated Pembrolizumab Quavonlimab (MK 1308A) Versus Other Treatments in Participants With Microsatellite Instability High (MSI H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK 1308A 008 KEYSTEP 008)
NCT04895722 — cells, b7-h1 antigen, dna mismatch repair, lewy bodies, microsatellite repeats, parkinson disease, neoplasms, multiple chronic conditions, therapeutics, colorectal neoplasms, ligands, cell death, microsatellite instability, mmr-deficient, msi-h		Phase 2Active not recruiting2021

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS